ICICI Prudential Nifty Pharma Index Fund - IDCW - Direct Plan

Other Plans and Options
  • (-1.93%)Nav, as on 21-02-2025

  • Previous Nav

  • Net Change on 21-02-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
NIFTY PHARMA - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Axis Nifty 100 Index Fund - Direct Plan - IDCW Oct 18, 2019 4.04 11.20 14.88 0.21 1,680.51
Sundaram Nifty 100 Equal Weight Fund (Formerly Known as Principal Nifty 100 Equal Weight Fund)- Direct Plan - Income Distribution CUM Capital Withdrawal Option Jan 01, 2013 2.28 13.83 17.35 0.47 96.35

Fund Holdings as on 31-January-2025

  • Sun Pharmaceutical Industries Ltd.

  • Cipla Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Divi's Laboratories Ltd.

  • Lupin Ltd.

  • Aurobindo Pharma Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Alkem Laboratories Ltd.

  • Mankind Pharma Ltd

  • Zydus Lifesciences Ltd.

  • Laurus Labs Ltd.

  • Glenmark Pharmaceuticals Ltd.

  • IPCA Laboratories Ltd.

  • Biocon Ltd.

  • Abbott India Ltd.

  • J.B.Chemicals & Pharmaceuticals Ltd.

  • Gland Pharma Ltd.

  • Ajanta Pharma Ltd.

  • Natco Pharma Ltd.

  • Granules India Ltd.

  • TREPS

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Miscellaneous

View More

Fund Manager

  • Cash

  • Equity

View More

About ICICI Prudential Nifty Pharma Index Fund

Scheme Analysis

ICICI Prudential Nifty Pharma Index Fund is a Index Funds - Other fund and belongs to ICICI Prudential Mutual Fund. It was launched on 14-Dec-2022 and currently has an AUM of ₹86.46 crore. ICICI Prudential Nifty Pharma Index Fund is benchmarked against NIFTY 50 - TRI as primary index and NIFTY PHARMA - TRI as secondary index.

The NAV of ICICI Prudential Nifty Pharma Index Fund ended down ₹-0.31(-1.93%)yesterday to ₹15.7353.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The ICICI Prudential Nifty Pharma Index Fund is managed by Nishit Patel and Ashwini Shinde.

Fund House Contact

One BKC, A - Wing 13th Floor, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051

+91 (22) 2652 5000
enquiry@icicipruamc.com
+91 (22) 2652 8100